Precio de cierre
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
- EUR | -.--% | -.--% | -.--% |
23/05 | Los accionistas de Taro Pharmaceutical aprueban la fusión con Sun Pharmaceutical | MT |
20/05 | Aumentan los ingresos y los beneficios del cuarto trimestre fiscal de Taro Pharmaceutical Industries | MT |
Resumen de negocios
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Dermatological and Topical
68,0
%
| 337 | 60,0 % | 390 | 68,0 % | +15,68 % |
Other
12,0
%
| 101 | 18,0 % | 69 | 12,0 % | -31,96 % |
Neuropsychiatric
9,0
%
| 73 | 13,0 % | 52 | 9,0 % | -29,34 % |
Cardiovascular
6,0
%
| 34 | 6,0 % | 34 | 6,0 % | +2,07 % |
Anti-inflammatory
3,0
%
| 17 | 3,0 % | 17 | 3,0 % | +2,07 % |
Allergy
2,0
%
| - | - | 11 | 2,0 % | - |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
63,4
%
| 377 | 67,1 % | 363 | 63,4 % | -3,61 % |
Canada
23,8
%
| 130 | 23,2 % | 136 | 23,8 % | +4,75 % |
Israel
8,1
%
| 48 | 8,5 % | 46 | 8,1 % | -3,70 % |
Other
4,8
%
| 7 | 1,2 % | 28 | 4,8 % | +311,17 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 54 | 01/12/16 | |
William Coote
DFI | Director of Finance/CFO | 69 | 01/01/08 |
Richard Glaze
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Hagai Reingold
COO | Chief Operating Officer | - | 01/01/02 |
Avi Avramoff
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/10/11 |
James Kedrowski
BRD | Director/Board Member | 72 | 01/10/10 |
David Kinzelberg
AUD | Comptroller/Controller/Auditor | - | - |
Erik Zwicker
LAW | General Counsel | 44 | 13/04/20 |
Abhay Gandhi
PRN | Corporate Officer/Principal | 59 | 01/12/16 |
Michele Visosky
HRO | Human Resources Officer | 58 | 01/01/04 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Robert Stein
BRD | Director/Board Member | 73 | 01/02/20 |
Chairman | 68 | 22/09/10 | |
Director/Board Member | 67 | 01/09/10 | |
Oded Sarig
BRD | Director/Board Member | 68 | 27/06/23 |
Chief Executive Officer | 54 | 01/12/16 | |
James Kedrowski
BRD | Director/Board Member | 72 | 01/10/10 |
Director/Board Member | 59 | 01/12/16 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 3 719 | 2 600 | 0 | 0 | 17,92 % |
Acción B | 1 | 45 116 262 | 8 086 818 ( 17,92 %) | 7 531 631 ( 16,69 %) |
Información de la empresa
Taro Pharmaceutical Industries Ltd.
14 Hakitor Street
2624761, Haifa Bay
+972 4 847 5700
http://www.taro.comVentas por actividad
Ventas por región
Varia. 1 de ene. | Capi. | |
---|---|---|
+39,22 % | 727 mil M | |
+30,57 % | 592 mil M | |
-7,85 % | 347 mil M | |
+15,48 % | 319 mil M | |
-0,12 % | 274 mil M | |
+12,55 % | 238 mil M | |
+6,65 % | 204 mil M | |
-6,09 % | 203 mil M | |
-3,37 % | 160 mil M |
- Bolsa de valores
- Acciones
- Acción TARO
- Acción TAL
- Empresa Taro Pharmaceutical Industries Ltd.